MAP2K7 and hepatocellular carcinoma: Sorafenib, the only approved drug for HCC, inhibited tumor angiogenesis and induced tumor cell apoptosis by blocking the RAF/MEK/ERK pathway22, suggesting that MAPK signaling pathways, especially ERK/MAPK pathway, might play an important role in HCC.